Sarah Cannon Research Institute shared on LinkedIn:
“Dr. Meredith McKean‘s recent discussion on PD-1–refractory advanced melanoma at ecancer underscores our commitment to navigating through the toughest challenges in cancer treatment. Her insights are showing how this research is paving the way to new therapeutic strategies.”.
Read further.
Source: Sarah Cannon Research Institute/LinkedIn